A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects.
Fiche publication
Date publication
avril 2021
Journal
Clinical and experimental rheumatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
Tous les auteurs :
Perrineau S, Ghesquière T, Charles P, Paule R, Samson M, Gayraud M, Chauvin A, Terrier B, Guillevin L, Bonnotte B, Mouthon L, Régent A,
Lien Pubmed
Résumé
Giant cell arteritis (GCA) is the most common primary large-vessel vasculitis. Glucocorticoids (GC) therapy remains the standard of care for GCA despite frequent side effects (SEs). However, treatment modality changes, prophylactic treatment of osteoporosis, or vaccinations might have decreased the frequency of GC-related SEs. This study aims to describe GCA treatment and GC-related SEs in a recent cohort.
Référence
Clin Exp Rheumatol. 2021 Apr 30;: